Accumulating evidence has suggested that the T2DM medication SGLT2 inhibitors provide antioxidative effects and mitochondrial protection in human disease models including hepatic, renal, cardiac, and nervous conditions. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.